UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): October 14, 2014

 

InspireMD, Inc.

 

(Exact name of registrant as specified in its charter)

 

Delaware   001-35731   26-2123838
(State or other
jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

321 Columbus Avenue    
Boston, Massachusetts   02116
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (857) 453-6553

 

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 2.02Results of Operations and Financial Condition.

 

On October 14, 2014, InspireMD, Inc. (the “Company”) issued a press release announcing commercial, development and clinical updates on the MGuard Prime Embolic Protection Systems (EPS) product line and new product programs and hosted a conference call at 8:30am ET to review the updates reported in the press release. During the course of the conference call, the Company announced that the revenue generated from MGuard Prime sales during the three month period ended September 30, 2014 was approximately $220,000, and that the Company’s monthly negative cash flow during the three month period ended September 30, 2014 should be slightly less than the Company’s historical monthly negative cash flow of $1.3 million to $1.6 million. An archive of the conference call is accessible on the Investor Relations section of the Company’s website at www.inspire-md.com/site_en/for-investors and will be accessible for a limited time.

 

In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02 in this Current Report on Form 8-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 7.01Regulation FD Disclosure.

 

The information required to be disclosed under this Item 7.01 is set forth above under Item 2.02.

 

Item 8.01Other Events.

 

On October 14, 2014, the Company issued a press release announcing commercial, development and clinical updates on the MGuard Prime EPS product line and new product programs. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 9.01Financial Statements and Exhibits.

 

(d)Exhibits

 

Exhibit
Number		   Description
99.1   Press release dated October 14, 2014

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  inspiremd, inc.  
       
Date: October 14, 2014 By:  /s/ Craig Shore  
    Name: Craig Shore  
    Title: Chief Financial Officer